Angiopoietin-2
-
Subject Areas on Research
- A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.
- Angiopoietin-1 enhances skeletal muscle regeneration in mice.
- Angiopoietin-2 confers Atheroprotection in apoE-/- mice by inhibiting LDL oxidation via nitric oxide.
- Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2.
- Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis.
- Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.
- Infection-Induced Vascular Permeability Aids Mycobacterial Growth.
- Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer.
- Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2.
- Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease.
- Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth.
- Tie1: an orphan receptor provides context for angiopoietin-2/Tie2 signaling.
- VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling.